Pliant Therapeutics Inc (PLRX) is a Healthcare · Biotechnology company listed on NASDAQ. Price $1.10 (-2.65%), Market cap $0.07B, 52-week low–high $1.09 ~ $1.87.
Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company's lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of avß8 and avß1 integrins that is in Phase 1a/1b for the treatment of solid tumors. It is also developing drug discovery platform comprising proprietary library of over 15,000 integrin binding molecules, focusing on integrin-based target-mediated drug delivery. Pliant Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Financial statements, price targets, institutional (13F) holdings and related news for Pliant Therapeutics Inc are updated in real time on BlackAll Trade.
Pliant Therapeutics Inc trades at $1.10 (-2.65%). Real-time quotes and charts are available on BlackAll Trade.
Pliant Therapeutics Inc has a market cap of about $0.07B.
Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company's lead product c